Novartis study of Afinitor® in advanced liver cancer does not meet primary endpoint of overall survival
Novartis announced Tuesday (07.08.2013) that results of a global Phase III study showed that Afinitor® (everolimus) did not extend overall survival compared to placebo in patients with locally advanced or metastatic hepatocellular carcinoma (HCC) after […]